Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $139,860.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the sale, the insider directly owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sharon Townson also recently made the following trade(s):

• On Tuesday, June 23rd, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $60,000.00.
• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total value of $57,000.00.

Monte Rosa Therapeutics Stock Up 4.9%

Shares of GLUE traded up $1.15 during midday trading on Tuesday, reaching $24.40. 1,302,330 shares of the stock were exchanged, compared to its average volume of 1,374,370. The stock’s 50 day simple moving average is $19.43 and its 200 day simple moving average is $18.93. The company has a market cap of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.56. Monte Rosa Therapeutics, Inc. has a twelve month low of $4.12 and a twelve month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Institutional Trading of Monte Rosa Therapeutics

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Monte Rosa Therapeutics by 8.6% in the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after acquiring an additional 257,547 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at approximately $778,000. Strs Ohio acquired a new position in Monte Rosa Therapeutics during the 4th quarter worth approximately $566,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares during the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in Monte Rosa Therapeutics in the 4th quarter valued at approximately $63,000. 79.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GLUE has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Finally, Guggenheim upped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.